GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Cyclically Adjusted Revenue per Share

Xintela AB (OSTO:XINT) Cyclically Adjusted Revenue per Share : kr0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xintela AB's adjusted revenue per share data for the fiscal year that ended in Dec. 2023 was kr0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-24), Xintela AB's current stock price is kr 0.482. Xintela AB's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2023 was kr0.00. Xintela AB's Cyclically Adjusted PS Ratio of today is .


Xintela AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Xintela AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Cyclically Adjusted Revenue per Share Chart

Xintela AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xintela AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xintela AB's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Xintela AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xintela AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xintela AB's Cyclically Adjusted PS Ratio falls into.



Xintela AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xintela AB's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/131.9118*131.9118
=0.000

Current CPI (Dec. 2023) = 131.9118.

Xintela AB Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.012 100.225 0.016
201512 0.026 100.276 0.034
201612 0.000 102.022 0.000
201712 0.000 103.793 0.000
201812 0.028 105.912 0.035
201912 0.001 107.766 0.001
202012 0.000 108.296 0.000
202112 0.000 112.486 0.000
202212 0.000 126.365 0.000
202312 0.000 131.912 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Xintela AB  (OSTO:XINT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xintela AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Xintela AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Xintela AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.

Xintela AB Headlines

No Headlines